Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Reata Pharmaceuticals Inc's Business Segments
Reata Pharmaceuticals Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
-
Largest Segment
-
Total Revenue
$ 23
Regions Reported
-
Reata Pharmaceuticals Inc does not report a distinct business-segment axis in its filings - its disaggregated revenue is disclosed by product and service category instead. See the Product & Service breakdown below.
Revenue by Product & Service Category - FY
- Product88.1%
- Service, Other11.9%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 20 | 88.1% |
| Service, Other | $ 3 | 11.9% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Reata Pharmaceuticals Inc
Reata Pharmaceuticals Inc. is a biopharmaceutical company that is dedicated to the discovery, development, and commercialization of novel therapeutics for patients with serious or life-threatening diseases. The company was founded in 2002 and is headquartered in Texas, United States.
Reata is focused on developing small molecule drugs that target specific signaling pathways that underlie diseases such as chronic kidney disease, rare genetic diseases, and various forms of cancer. The company's approach is to develop drugs that target specific cellular pathways that are involved in disease progression, including oxidative stress, inflammation, and cellular metabolism.
One of Reata's lead drug candidates is bardoxolone methyl, which is under development for multiple rare and severe conditions. It is a potent activator of a transcription factor called Nrf2, which plays a key role in regulating the body's response to oxidative stress and inflammation. Bardoxolone methyl is currently in clinical trials for chronic kidney disease, pulmonary arterial hypertension, and Alport syndrome.
Another promising drug candidate in Reata's pipeline is omaveloxolone, which is being studied for the treatment of Friedreich's ataxia, a rare genetic disease that affects the nervous system and causes balance problems, difficulty walking, and other symptoms. Omaveloxolone is also being evaluated for the treatment of mitochondrial myopathy, a rare disorder that affects the production of energy within cells.
In addition to its clinical development programs, Reata has a growing portfolio of preclinical programs focused on developing drugs for various types of cancer, including pancreatic cancer and other solid tumors. The company's preclinical pipeline also includes drug candidates for the treatment of rare inherited diseases such as polycystic kidney disease.
Reata has a strong track record of advancing its drug candidates through clinical development and securing FDA approvals. The company has a strategic partnership with Kyowa Kirin Co. Ltd., a global pharmaceutical company, to develop and commercialize bardoxolone methyl in certain territories outside of the United States.
Overall, Reata Pharmaceuticals is a highly innovative biopharmaceutical company that is making significant progress in the development of novel therapeutics for patients with serious and life-threatening diseases. The company's focus on developing drugs that target specific cellular pathways involved in disease progression has the potential to transform the treatment of a range of diseases and improve outcomes for patients.
Reata is focused on developing small molecule drugs that target specific signaling pathways that underlie diseases such as chronic kidney disease, rare genetic diseases, and various forms of cancer. The company's approach is to develop drugs that target specific cellular pathways that are involved in disease progression, including oxidative stress, inflammation, and cellular metabolism.
One of Reata's lead drug candidates is bardoxolone methyl, which is under development for multiple rare and severe conditions. It is a potent activator of a transcription factor called Nrf2, which plays a key role in regulating the body's response to oxidative stress and inflammation. Bardoxolone methyl is currently in clinical trials for chronic kidney disease, pulmonary arterial hypertension, and Alport syndrome.
Another promising drug candidate in Reata's pipeline is omaveloxolone, which is being studied for the treatment of Friedreich's ataxia, a rare genetic disease that affects the nervous system and causes balance problems, difficulty walking, and other symptoms. Omaveloxolone is also being evaluated for the treatment of mitochondrial myopathy, a rare disorder that affects the production of energy within cells.
In addition to its clinical development programs, Reata has a growing portfolio of preclinical programs focused on developing drugs for various types of cancer, including pancreatic cancer and other solid tumors. The company's preclinical pipeline also includes drug candidates for the treatment of rare inherited diseases such as polycystic kidney disease.
Reata has a strong track record of advancing its drug candidates through clinical development and securing FDA approvals. The company has a strategic partnership with Kyowa Kirin Co. Ltd., a global pharmaceutical company, to develop and commercialize bardoxolone methyl in certain territories outside of the United States.
Overall, Reata Pharmaceuticals is a highly innovative biopharmaceutical company that is making significant progress in the development of novel therapeutics for patients with serious and life-threatening diseases. The company's focus on developing drugs that target specific cellular pathways involved in disease progression has the potential to transform the treatment of a range of diseases and improve outcomes for patients.
Reata Pharmaceuticals Inc. Overview
Reata Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the development of innovative therapies for patients suffering from serious diseases, including chronic kidney disease (CKD), rare genetic disorders, and various forms of cancer. The company aims to address unmet medical needs through a comprehensive portfolio that spans multiple therapeutic areas.
Segments
1. Oncology
- The oncology division concentrates on the research and development of therapies that target various types of cancer. The focus is particularly on aggressive forms of cancer, such as pancreatic cancer, lung cancer, and breast cancer. Reata seeks to create novel therapeutic agents that not only extend survival but also enhance the quality of life for cancer patients.
2. Genetic Diseases
- In the genetic diseases segment, Reata Pharmaceuticals is committed to developing treatments for rare genetic disorders. This includes agonistic work on conditions such as Alport syndrome, which affects kidney function, and Friedreichs ataxia, a debilitating hereditary condition that impacts movement. The segment also dedicates research towards various mitochondrial diseases which can severely affect multiple organ systems.
3. Chronic Kidney Disease (CKD)
- CKD is a central area of focus given the rising prevalence of this condition. The company is involved in creating therapies that target the pathways associated with kidney function and regeneration, aiming to halt or reverse the progression of CKD.
Products
1. Bardoxolone
- Bardoxolone is a novel compound with a mechanism of action focused on modulating the Nrf2 signaling pathway, which aids in cellular defense mechanisms. This drug has been granted Breakthrough Therapy Designation by the FDA for the treatment of CKD stemming from various conditions. Its therapeutic role focuses on reducing inflammation and oxidative stress, which are pivotal to the pathophysiology of CKD.
2. Omaveloxolone
- Omaveloxolone is designed for the treatment of rare mitochondrial disorders, particularly Friedreichs ataxia. By acting as a targeted covalent inhibitor of the Nrf2 pathway, this first-in-class therapy showcases potential in improving neurological function and addressing the biochemical deficits in patients with such genetic conditions.
3. RTA 1701
- RTA 1701 is an oral small molecule medication specifically developed for Alport syndrome. By activating the Nrf2 signaling pathway, this product aims to provide a new therapeutic option that could alter the disease course and improve outcomes in patients facing this genetic disorder. Initial preclinical results have indicated promise in enhancing kidney function and reducing progression towards end-stage renal disease.
Services
1. Clinical Research
- Reata Pharmaceuticals conducts extensive clinical research to evaluate the safety and efficacy of its investigational products through a variety of clinical trials. This research is essential not only for regulatory approval but also for understanding the potential impact these therapies can have on patients’ lives.
2. Patient Support Services
- To enhance the overall patient experience, Reata provides comprehensive patient support services, including medication management, education programs to empower patients and caregivers, and financial assistance to minimize the burden associated with the high costs of treatment. This support framework ensures that patients can access their care pathways effectively.
Conclusion
Reata Pharmaceuticals Inc. stands at the forefront of biopharmaceutical innovation, particularly in the treatment of serious diseases. The companys commitment to addressing significant unmet medical needs through a diverse portfolio of segments, cutting-edge products, and dedicated services showcases its mission to improve patient outcomes and quality of life. By actively engaging in research and developing effective therapies, Reata aims to build a future where patients with chronic kidney disease, rare genetic disorders, and cancer have access to meaningful treatment options.
Reata Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the development of innovative therapies for patients suffering from serious diseases, including chronic kidney disease (CKD), rare genetic disorders, and various forms of cancer. The company aims to address unmet medical needs through a comprehensive portfolio that spans multiple therapeutic areas.
Segments
1. Oncology
- The oncology division concentrates on the research and development of therapies that target various types of cancer. The focus is particularly on aggressive forms of cancer, such as pancreatic cancer, lung cancer, and breast cancer. Reata seeks to create novel therapeutic agents that not only extend survival but also enhance the quality of life for cancer patients.
2. Genetic Diseases
- In the genetic diseases segment, Reata Pharmaceuticals is committed to developing treatments for rare genetic disorders. This includes agonistic work on conditions such as Alport syndrome, which affects kidney function, and Friedreichs ataxia, a debilitating hereditary condition that impacts movement. The segment also dedicates research towards various mitochondrial diseases which can severely affect multiple organ systems.
3. Chronic Kidney Disease (CKD)
- CKD is a central area of focus given the rising prevalence of this condition. The company is involved in creating therapies that target the pathways associated with kidney function and regeneration, aiming to halt or reverse the progression of CKD.
Products
1. Bardoxolone
- Bardoxolone is a novel compound with a mechanism of action focused on modulating the Nrf2 signaling pathway, which aids in cellular defense mechanisms. This drug has been granted Breakthrough Therapy Designation by the FDA for the treatment of CKD stemming from various conditions. Its therapeutic role focuses on reducing inflammation and oxidative stress, which are pivotal to the pathophysiology of CKD.
2. Omaveloxolone
- Omaveloxolone is designed for the treatment of rare mitochondrial disorders, particularly Friedreichs ataxia. By acting as a targeted covalent inhibitor of the Nrf2 pathway, this first-in-class therapy showcases potential in improving neurological function and addressing the biochemical deficits in patients with such genetic conditions.
3. RTA 1701
- RTA 1701 is an oral small molecule medication specifically developed for Alport syndrome. By activating the Nrf2 signaling pathway, this product aims to provide a new therapeutic option that could alter the disease course and improve outcomes in patients facing this genetic disorder. Initial preclinical results have indicated promise in enhancing kidney function and reducing progression towards end-stage renal disease.
Services
1. Clinical Research
- Reata Pharmaceuticals conducts extensive clinical research to evaluate the safety and efficacy of its investigational products through a variety of clinical trials. This research is essential not only for regulatory approval but also for understanding the potential impact these therapies can have on patients’ lives.
2. Patient Support Services
- To enhance the overall patient experience, Reata provides comprehensive patient support services, including medication management, education programs to empower patients and caregivers, and financial assistance to minimize the burden associated with the high costs of treatment. This support framework ensures that patients can access their care pathways effectively.
Conclusion
Reata Pharmaceuticals Inc. stands at the forefront of biopharmaceutical innovation, particularly in the treatment of serious diseases. The companys commitment to addressing significant unmet medical needs through a diverse portfolio of segments, cutting-edge products, and dedicated services showcases its mission to improve patient outcomes and quality of life. By actively engaging in research and developing effective therapies, Reata aims to build a future where patients with chronic kidney disease, rare genetic disorders, and cancer have access to meaningful treatment options.